What's Happening?
Glaukos Corporation has announced the commercial availability of Epioxa, a new FDA-approved topical drug therapy for keratoconus, a rare corneal disease. Epioxa offers an incision-free alternative to traditional corneal cross-linking procedures, aiming
to improve patient comfort and reduce recovery time. The therapy is designed to address the underdiagnosis and undertreatment of keratoconus by providing a more accessible and less invasive treatment option. Glaukos plans to enhance patient awareness and access through various support programs, including co-pay assistance and patient access liaison teams, to ensure broader reach and impact.
Why It's Important?
The introduction of Epioxa represents a significant advancement in the treatment of keratoconus, offering a less invasive and more patient-friendly option. This development could lead to increased diagnosis and treatment rates, improving outcomes for patients who suffer from this sight-threatening condition. By reducing the barriers to treatment, Glaukos is addressing a critical gap in eye care, potentially setting a new standard for keratoconus management. The company's commitment to patient support and education further underscores the importance of accessibility in healthcare innovations.
